Theravance Biopharma Inc. | Mutual Funds
Mutual Funds that own Theravance Biopharma Inc.
CF Woodford Equity Income
10,018,839
18.18%
55,000
3.71%
07/31/2018
Fidelity Select Health Care Portfolio
1,252,066
2.27%
0
0.48%
07/31/2018
Fidelity Puritan Fund
1,116,700
2.02%
0
0.12%
07/31/2018
Fidelity Growth Company Fund
1,062,124
1.93%
-5,763
0.06%
07/31/2018
Vanguard Small Cap Index Fund
1,035,388
1.88%
14,739
0.03%
07/31/2018
Vanguard Total Stock Market Index Fund
1,003,208
1.82%
1,150
0%
07/31/2018
iShares Russell 2000 ETF
896,744
1.63%
-480
0.05%
09/06/2018
Government Pension Fund - Global (The)
774,797
1.41%
-91,927
0%
12/31/2017
iShares Nasdaq Biotechnology ETF
633,362
1.14%
-8,274
0.19%
09/06/2018
T Rowe Price Health Sciences Fund
625,412
1.13%
625,412
0.14%
06/30/2018
| Address |
Ugland House
George Town GT KY1
Cayman Islands
|
|
Employees
|
- |
| Website |
http://www.theravance.com |
| Updated |
07/08/2019 |
| Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands. |
